GLP-1 Drug Costs and Pharmacy Risk in Self-Funded Health Plans for 2026

For self-funded employers, 2026 is the year pharmacy trend stopped being a line item and became the story. Segal projects prescription drug costs will rise roughly 11 percent this year—outpacing medical—and names GLP-1 medications as a top driver. Semaglutide and tirzepatide—marketed as Ozempic, Wegovy, Mounjaro, and Zepbound—have moved from diabetes management into large-scale obesity treatment, and the arithmetic is unforgiving. Wegovy carries a list price near $1,349 a month; Zepbound sits around $1,059. Even before rebates, a single covered member can add more than $12,000 a year to plan spend, and utilization rarely arrives one member at a time. That shift—from a targeted diabetes therapy to a mainstream weight-management benefit—is what turned a once-manageable class into the defining pharmacy risk of the year.

Where the exposure actually lives

The distinction that matters to a self-funded plan is coverage scope. Nearly every plan covers GLP-1s for type 2 diabetes; the open question is obesity. KFF's 2025 Employer Health Benefits Survey found that among the largest firms—5,000 or more workers—43 percent covered GLP-1s for weight loss, compared with 16 percent of firms with 200 to 999 workers. The Business Group on Health's 2026 survey put weight-management coverage at 67 percent of its large-employer members. Where coverage exists, demand has consistently run ahead of projections: two-thirds of the largest firms told KFF that covering these drugs for weight loss had a "significant" impact on prescription spend, and nearly eight in ten employers now say GLP-1s are driving up health care costs overall.

The exposure compounds because these are chronic, indefinite therapies—not a course of treatment with an endpoint. Yet adherence tells a more complicated story: Mercer, citing Prime Therapeutics data, notes that only about one in twelve members remain on treatment after three years. Discontinuation driven by side effects, cost, or supply gaps means the plan often funds the most expensive early months and little of the sustained benefit. A plan can pay premium prices for a population that churns—absorbing the acquisition cost without capturing the durable health outcome that would justify it.

The rebate problem you cannot see

Much of a self-funded plan's pharmacy risk is hidden not in the drug price but in the contract that governs it. Three pharmacy benefit managers—CVS Caremark, Express Scripts, and OptumRx—administer roughly 79 percent of U.S. prescription claims, and the economics that flow through them are famously opaque. Rebates negotiated with manufacturers, spread between what the plan pays and what the pharmacy receives, and formulary placement that favors higher-list, higher-rebate products all sit behind a wall many plan sponsors never see through. The result is a strange incentive: a rebate check can make an expensive drug feel affordable while the plan's gross cost keeps climbing. Independent auditing of PBM claims data—the kind a plan sponsor rarely thinks to demand—is often where hidden spread first becomes visible.

Reform is beginning to shift the ground. The Consolidated Appropriations package enacted in February 2026 requires 100 percent rebate pass-through to ERISA-covered plans and adds reporting on utilization and pricing, with Medicare compensation delinking from drug prices arriving in 2028. These are structural improvements—but they do not relieve a plan sponsor of the fiduciary work of reading its own contract. Transparency you are handed is not the same as transparency you have verified.

Plan-design levers that surface and control trend

Control does not require exclusion, though exclusion remains a legitimate choice. Between blanket coverage and no coverage lies a spectrum of intentional design. Clinical eligibility criteria—BMI thresholds, documented comorbidities, enrollment in an accompanying lifestyle or coaching program—keep therapy aligned with clinical need. Prior authorization and step therapy create a defensible gate. Cost-sharing structure matters too: the Business Group on Health found 83 percent of employers apply standard cost-share to GLP-1s, leaving room for differentiated designs that share more of the cost signal with members. Steering toward the lowest-net-cost option within the class can bend spend without withdrawing access, and reauthorization tied to demonstrated progress stops the plan from paying for therapy that has quietly lapsed.

None of these levers is a torch you light once and forget—they demand monitoring, because utilization, list prices, and the drug pipeline all keep moving. Oral GLP-1s now on the horizon are expected to widen demand further, and 87 percent of employers anticipate exactly that.

This is where a structured process earns its keep. At PFTN we work a self-funded plan's pharmacy exposure through four stages—Strategic Discovery to map current spend, contracts, and utilization; Risk Assessment to quantify GLP-1 and specialty trend against the plan's runway; Solution Design to craft the eligibility, authorization, and cost-share architecture that fits the workforce; and Ongoing Optimization to keep the design honest as prices and clinical evidence evolve. Ownership of pharmacy trend is not a single decision. It is a discipline—one a self-funded employer is uniquely positioned to exercise, because the dollars, and the leverage, are its own.